Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: A case-control study - 15/11/14

Michael Y. Xiong, BA ^{a, b}, Michael S. Rabkin, MD, PhD ^{c, ⁎} , Michael W. Piepkorn, MD, PhD ^d, Raymond L. Barnhill, MD ^e, Zsolt Argenyi, MD ^d, Lori Erickson, MD ^f, Joan Guitart, MD ^g, Lori Lowe, MD ⁱ, Christopher R. Shea, MD ^h, Martin J. Trotter, MD, PhD ^j, Robert A. Lew, PhD ^k, Martin A. Weinstock, MD, PhD ^{a, b, l, m}

^a Dermatoepidemiology Unit, VA Medical Center, Providence, Rhode Island 

^b Department of Dermatology, Alpert Medical School, Brown University, Providence, Rhode Island 

^c Rabkin Dermatopathology Laboratory PC, Tarentum, Pennsylvania 

^d Department of Medicine/Dermatology, University of Washington Medical Center, Seattle, Washington 

^e Department of Pathology and Laboratory Medicine, University of California, and Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California 

^f Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 

^g Department of Dermatology, Northwestern University, Chicago, Illinois 

^h Sand Section of Dermatology, University of Chicago Medicine, Chicago, Illinois 

ⁱ Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan 

^j Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, University of Calgary, Canada 

^k Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Health Care System, Boston, Massachusetts 

^l Department of Dermatology, Rhode Island Hospital, Providence, Rhode Island 

^m Department of Epidemiology, Brown University, Providence, Rhode Island 

^∗Correspondence to: Michael S. Rabkin, MD, PhD, 419 East Second Avenue, Tarentum, PA 15084